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To the Editor:
Lara et al. have recently reported 
in this Journal a pooled analysis of 
three Southwest Oncology Group trials 
performed in 329 pretreated extensive-
stage small cell lung cancer (SCLC) 
patients aiming to assess whether plat-
inum-sensitivity status is associated 
with survival outcomes.1 Sensitivity 
to first-line chemotherapy has always 
been considered as the main driver of 
second-line therapy outcome in SCLC. 
For this reason, relapsed SCLC has 
been traditionally classified into sensi-
tive and resistant disease according to 
the type of response to first-line ther-
apy and to treatment-free interval (TFI, 
longer or shorter than 60–90 days). 
However, as also underlined by Lara et 
al., this definition was designed many 
years ago and based on a small patient 
series,2 and its validity has been put 
under discussion by some more recent 
studies.1,3
On the basis of this consider-
ations, we have recently performed a 
meta-analysis of six trials of intrave-
nous topotecan-based second-line ther-
apy aimed at validating the currently 
used criteria for defining sensitive/
resistant relapsed SCLC and to assess 
the prognostic impact of sensitive/resis-
tant categories and of other clinical fac-
tors.4 Our study has confirmed the value 
of standard criteria for relapsed SCLC 
outcome prediction. In particular, 
patients with TFI less than 60 days had 
a worse survival outcome; in addition, 
is, cytotoxic agent was included in 
only one of the three trials.
The concept of platinum sensi-
tivity was established based on retro-
spective analysis of the clinical trials 
of second-line chemotherapy with 
cytotoxic agents,2,3,4 and the useful-
ness of the concept has been con-
firmed as long as we used cytotoxic 
agents for second-line treatment.5,6 
The authors’ conclusion may be cor-
rect when noncytotoxic agents, such 
as molecularly targeted agents, are 
used for second-line chemotherapy; 
however, we believe that the tradi-
tional concept still works and should 
be referred to as ever when cytotoxic 
agents are used as second-line treat-
ment in both clinical trial and clinical 
practice settings.
Young Hak Kim, MD, PhD
Michiaki Mishima, MD, PhD
Department of Respiratory Medicine




 1. Lara PN Jr, Moon J, Redman MW, et al. 
Relevance of platinum-sensitivity status in 
relapsed/refractory extensive-stage small-
cell lung cancer in the modern era: A patient-
level analysis of southwest oncology group 
trials. J Thorac Oncol 2015;10:110–115.
 2. Postmus PE, Berendsen HH, van Zandwijk 
N, Splinter TA, Burghouts JT, Bakker W. 
Retreatment with the induction regimen in 
small cell lung cancer relapsing after an ini-
tial response to short term chemotherapy. Eur 
J Cancer Clin Oncol 1987;23:1409–1411.
 3. Giaccone G, Ferrati P, Donadio M, Testore 
F, Calciati A. Reinduction chemotherapy in 
small cell lung cancer. Eur J Cancer Clin 
Oncol 1987;23:1697–1699.
 4. Johson DH, Greco FA, Strupp J, Hande KR, 
Hainsworth JD. Prolonged administration of 
oral etoposide in patients with relapsed or 
refractory small-cell lung cancer: A phase II 
trial. J Clin Oncol 1990;8:1613–1617.
 5. Kim YH, Goto K, Yoh K, et al. Performance status 
and sensitivity to first-line chemotherapy are sig-
nificant prognostic factors in patients with recur-
rent small cell lung cancer receiving second-line 
chemotherapy. Cancer 2008;113:2518–2523.
 6. Kim YH, Mio T, Masago K, Irisa K, Sakamori 
Y, Mishima M. Retrospective analysis of 
Japanese patients with relapse or refractory 
small-cell lung cancer treated with amrubicin 




Is Platinum Sensitivity 
a Relevant Prognostic 
Factor?
Address for correspondence: Young Hak Kim, 
MD, PhD, Department of Respiratory 
Medicine, Graduate School of Medicine, 
Kyoto University, 54 Shogoin-Kawaracho, 








Address for correspondence: Marcello Tiseo, 
Medical Oncology Unit, University Hospital 
of Parma, Via Gramsci 14, Parma 43125, 
Italy. E-mail: mtiseo@ao.pr.it
To the Editor:
Lara et al. have recently reported 
a retrospective study on data from the 
Southwest Oncology Group aiming 
to evaluate the association between 
platinum-sensitivity status and clini-
cal outcome in patients with relapsed 
or refractory small-cell lung cancer. In 
the study, patient-level data from three 
recent Southwest Oncology Group tri-
als for second-line and/or third-line 
extensive-stage small-cell lung cancer 
were pooled and analyzed, and they 
concluded that platinum-sensitivity 
status might no longer be as strongly 
associated with post-progression sur-
vival in the modern era.1
In the article, they mentioned 
a defect of their study in that tri-
als included in their analysis had no 
or little activity, and they stated that 
they, therefore, could not rule out the 
possibility that platinum-sensitivity 
status might influence the outcome 
in patients receiving active therapies; 
however, they did not refer to the bias 
of the included trials in their analysis, 
and we consider that this is a critical 
defect of the study. Trials included 
in their analysis were for bortezo-
mib (proteasome inhibitor), sorafenib 
(vascular endothelial growth factor 
receptor tyrosine kinase inhibitor), 
and topotecan ± aflibercept (vascular 
endothelial growth factor-trap); that 
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